Avelumab + Docetaxel Scores 52% ORR in Platinum-Refractory or -Ineligible mUrothelial Carcinoma

Take home

If larger studies replicate these double-digit survival figures with manageable myelosuppression, docetaxel-plus-avelumab could fill a chemo-immunotherapy niche for patients who fail—or cannot take—platinum regimens in advanced bladder cancer. However, in comparison with enfortumab vedotin plus pembrolizumab, the preferred first-line regimen for cisplatin-ineligible patients, with ORR 67.7%, median PFS 12.5 months, and median OS 31.5 months, it would appear that docetaxel-plus-avelumab won’t be more effective though perhaps better tolerated since enfortumab vedotin plus pembrolizumab has a discontinuation rate occurring in about 35% of patients, most often due to skin toxicity or neuropathy.